Loading...
Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial
Зохиогч
Batmunkh, Tsetsegsaikhan
Neal, Eleanor Fg
Amraa, Otgonjargal
Mazarakis, Nadia
Altangerel, Bolor
Avaa, Naranbaatar
Batbayar, Lkhagvagaram
Batsukh, Khishigjargal
Bright, Kathryn
Burentogtokh, Tsogjargal
Do, Lien Anh Ha
Hart, John D
Jamiyandorj, Otgonbold
Javkhlantugs, Khulan
Jigjidsuren, Sarantsetseg
Justice, Frances
Li, Shuo
Mashbaatar, Khaliunaa
Moore, Kerryn A
Namjil, Narantuya
Nguyen, Cattram D
Ochirbat, Batbayar
Surenjav, Unursaikhan
Thomson, Helen
Licciardi, Paul V
von Mollendorf, Claire
Mulholland, Kim
Он
2026
Төрөл
journal article
Journal
Frontiers in immunology
Volume
17
Start Page
1789248
ISSN
1664-3224
Хураангуй
INTRODUCTION: COVID-19 boosters restore waning immunity. After demonstrating non-inferiority of 15 μg versus 30 μg BNT162b2 at 28 days in Mongolian adults, we assessed 24-month immunogenicity and safety.
METHODS: In this randomised, controlled trial, adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were assigned (1:1) to 15 μg or 30 μg BNT162b2. Anti-spike IgG, surrogate virus neutralisation (sVNT) against Wuhan-Hu-1 and Omicron BA.1, and interferon-gamma (IFN-γ) release assays (Ag1/Ag2) were assessed to 24 months. SARS-CoV-2 infections and serious adverse events (SAEs) were recorded. ClinicalTrials.gov: NCT05265065.
RESULTS: Of 601 participants, 520 (86.5%) completed follow-up. IgG and IFN-γ responses were comparable between arms at 24 months (IgG geometric mean ratio (GMR) 1.06 [95% CI 0.95-1.18]; Ag1 GMR 1.17 [95% CI 0.82-1.66]; Ag2 GMR 1.06 [95% CI 0.73-1.54]). Median sVNT inhibition remained high (Wuhan-Hu-1 88% [interquartile range (IQR) 86-90]; Omicron BA.1 85% [IQR 70-88]). Twenty-eight SARS-CoV-2 infections occurred. Fifty-three SAEs were balanced by study arm, and none were vaccine related.
DISCUSSION: Equivalent immunity and safety from 15 μg and 30 μg BNT162b2 boosters support fractional dosing as a cost-saving strategy.
CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT05265065, identifier NCT05265065.
